Anti-Mouse CD370 (CLEC9A/DNGR1) In Vivo Antibody - Ultra Low Endotoxin
Introducing the Anti-Mouse CD370 (CLEC9A/DNGR1) In Vivo Antibody - Ultra Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the CD370 protein, crucial for recognizing necrotic cells and cross-presenting antigens, making it ideal for research in immunology and dendritic cell biology.
With a rat IgG2a kappa isotype, it ensures high purity and ultra-low endotoxin levels (<0.01 EU/μg), perfect for ELISA, flow cytometry, immunohistochemistry, and other assays. Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy. Enhance your research with this reliable and versatile antibody. CD370, also known as CLEC9A or DNGR1, is a type II transmembrane receptor expressed on a subset of dendritic cells and cytotoxic T cells. It plays a significant role in the immune system by recognizing damaged cells and facilitating antigen cross-presentation, crucial for initiating immune responses.
Product Name:
Anti-Mouse CD370 (CLEC9A/DNGR1) In Vivo Antibody - Ultra Low Endotoxin
Product Code:
IVMB0372
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
1F6
Protein:
CD370
Product Type:
Monoclonal Antibody
Synonyms:
CD370, DNGR-1, C-Type Lectin Domain Family 9 Member A
Isotype:
IgG1
Reactivity:
Mouse
Applications:
FC, IF, In Vivo, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
≤ 0.5 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
FC, IF, In Vivo, WB
Reactivity:
Mouse
Host Species:
Mouse
Specificity:
This clone 1F6 monoclonal antibody recognizes a direct epitope on mouse DNGR1/CLEC9A for CD8+ dendritic cells, which can be exploited for tumor therapy, whilst also recognizing necrotic cells. This antibody can recognize both the short and long isoform of DNGR-1, which varies in a segment of the stalk region.
Antigen Distribution:
CD370 (CLEC9A) in mice is expressed on CD8+ DCs and at low levels by plasmacytoid DCs
Immunogen:
RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
≤ 0.5 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
CLEC9A antibody, 1F6, recognizes C-type lectin domain family 9 member A (CLEC9A), also known as CD370 and DNGR-1. CLEC9A is a type II transmembrane glycoprotein that belongs to the C-type lectin superfamily. In mice and humans, CLEC9A is expressed by CD8a+ conventional dendritic cells (cDCs) in mice1,2 and BDCA3+ DCs in humans3, which are specialized for the cross-presentation of exogenous antigens on MHC class I4. In mice, type I interferon (IFN)-secreting plasmacytoid DCs (pDCs) also express CLEC9A2. The ligand for CLEC9A is filamentous actin exposed on apoptotic cells5,6, and ligation of CLEC9A results in the cross-presentation and induction of CD8 T cell responses. CLEC9A is a target for vaccine enhancement, and antibodies targeting CLEC9A in vaccination studies lead to enhanced presentation by DCs, eliciting CD8 and CD4 T cell proliferation and strong humoral immunity. In addition, antigen targeting DCs via CLEC9A can enhance anti-tumor immunity12.
Protein:
CD370
Research Area:
Immunology, Innate Immunity
Pathogen Testing:
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Assay Genie's Purified Functional Antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
